Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
Viridian Therapeutics, Inc. (VRDN)
Company Research
Source: Yahoo! Finance
- Marketing Authorization Application (MAA) for veligrotug for TED submitted to the European Medicines Agency (EMA) in January 2026 - - Phase 3 topline data readout for subcutaneous elegrobart (VRDN-003) REVEAL-1 and REVEAL-2 studies on track for Q1 and Q2 2026 in active and chronic TED, respectively - - Advanced VRDN-008 into phase 1 clinical trial in healthy volunteers; data on track for 2H 2026 - - Strong balance sheet with cash, cash equivalents, and short-term investments of $875 million as of December 31, 2025 - - Based on existing cash, potential near-term milestones from 2025 royalty agreement, and anticipated commercial revenues, if both veligrotug and elegrobart are approved, the company expects current business plans to be funded through profitability - WALTHAM, Mass., February 26, 2026 BUSINESS WIRE )--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines fo
Show less
Read more
Impact Snapshot
Event Time:
VRDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRDN alerts
High impacting Viridian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VRDN
News
- What Viridian Therapeutics (VRDN)'s 2025 Losses and Thyroid Eye Disease Milestones Mean For Shareholders [Yahoo! Finance]Yahoo! Finance
- Viridian Therapeutics (VRDN) had its price target lowered by Royal Bank Of Canada from $45.00 to $42.00. They now have an "outperform" rating on the stock.MarketBeat
- Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial ResultsBusiness Wire
- Hot Picks: Biotech rebound turns to rare disease catalysts [BNN Bloomberg (Canada)]BNN Bloomberg
- Viridian Therapeutics (NASDAQ:VRDN) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $42.00 price target on the stock.MarketBeat
VRDN
Earnings
- 2/26/26 - Miss
VRDN
Sec Filings
- 3/4/26 - Form 4
- 3/4/26 - Form 4
- 3/4/26 - Form 4/A
- VRDN's page on the SEC website